Researchers are actively working on overcoming the limitations of AAV vectors: 1. Capsid modification: Engineering capsids to evade the immune system and enhance tissue-specific targeting. 2. Use of novel serotypes: Exploring different AAV serotypes or creating hybrid vectors to bypass pre-existing immunity. 3. Optimizing production: Developing more efficient production methods and purification techniques to scale up AAV vector availability.
